Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005872 · ClinicalTrials.gov registry record · Phase 2
Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00005872 is a Phase 2 study of Lung Cancer that has completed, run by Astex Pharmaceuticals. The trial reports 1 study location across 1 state.
The verdict
NCT00005872, a Phase 2 study of Lung Cancer, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have recurrent non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG rubitecan
Study Locations (1)
California
- SuperGen, Incorporated - Dublin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-05 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005872
The ClinicalTrials.gov registry entry for NCT00005872 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which rubitecan is the first listed.
NCT00005872 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00005872 about?
NCT00005872 is a clinical study titled "Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have recurrent non-small cell lung cancer.
What is the current status of trial NCT00005872?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-05. Estimated completion is 2004-04.
What conditions does trial NCT00005872 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00005872?
The interventions under investigation include: rubitecan (DRUG).
Who is sponsoring clinical trial NCT00005872?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005872 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.